ObjectiveTo observe the therapeutic effect of moxibustion on heat-sensitive acupoints on Bell's palsy.Methods102 patients with Bell's palsy were divided into observation group (n=52) and control group(n=50). The observation group was treated by moxibustion on the heat-sensitive acupoints plus physical therapy and medication, and the control group was only treated by physical therapy and medication. The therapeutic effect was assessed according to score of facial nerve function before and after the treatment.ResultsThe curative rate of 88.5% in the observation group was better than 62% in the control group. After treatment, the scores significantly improved in two groups (P<0.001), and were significantly better in the observation group than in the control group (P<0.01).ConclusionMoxibustion on the heat-sensitive acupoints has a high therapeutic effect on Bell's palsy.

AIM:To assess the protective role of melatonin(MEL)in a rat model of oleic-induced acute lung injury.METHODS:Twenty-four rats were randomly allocated to three groups as follows:saline(NS)injection group,oleic acid(OA)injection group and MEL plus OA injection group,the lavage protein,lung wet-to-dry weight ratio,malondialdehyde(MDA)content,superoxide dismutase(SOD)activity and lung histopathology were examined.RESULTS:(1)Injection 0.15 mL/kg of OA led to a severe acute lung injury(ALI),characterized by significantly increasing in lavage protein,lung coefficient(P＜0.01),and by histopathological alterations which presented hemorrhage,edema.thickened alveolar septum and the existence of inflammatory cells in alveolar spaces;(2)Infusion of MEL(20 mg/kg,intraperitoneally for 60 min before the oleic acid)markedly alleviated above-mentioned symptom induced by OA,consistent with decrease of MDA level(P＜0.01) and the increase of SOD activty(P＜0.01).CONCLUSION:Pre-treatment with MEL can attenuate the OA -induced ALI in rats via cleaning and preventing the formation of free radicals and further lessening the increase of alveolocapillary membrane permeability,these data suggest that MEL may be effective in the prevention of ALI.

Objective To study the effects of robot-assisted therapy combined with electromyographic biofeedback (EMGBF) on upper limb function after stroke.Methods Thirty acute stroke patients were randomly divided into two groups of 15.The patients in the control group received a conventional rehabilitation program and EMGBF.The patients in the treatment group received robot-assisted therapy for 30 minutes daily,6 days a week for 3 weeks combined with EMGBF on the basis of the conventional rehabilitation program.Upper limb motor function and ability in the activities of daily living (ADL) were assessed with the Fugl-Meyer upper extremity assessment (FMA) and a functional independence measure (FIM) before treatment,at 3 weeks and 3 months after treatment.Results After treatment the FMA and FIM scores of both groups were significantly better than before treatment.At 3 weeks after treatment there was no significant difference in the average FMA scores of the two groups,but at 3 months after treatment the patients in the treatment group had significantly better scores.No significant differences in FIM scores were observed at 3 weeks or 3 months.Conclusions Robot-assisted therapy combined with EMGBF can improve upper limb motor function significantly in acute stroke patients,and more effectively than EMGBF.But no significant advantage in improvement in ADL performance was observed with Robot-assisted therapy combined with EMGBF over EMGBF.

ObjectiveTo study the effect of partial body-weight support and treadmill training in subacute stroke patients.Methods40 stroke patients were randomly arranged into 3 groups: group A (n=14) accepted 8 weeks of routine physical therapy, group B (n=13) accepted additional 6 weeks partial body-weight support and treadmill training at the 3rd week, group C (n=13) accepted additional 3 weeks partial body-weight support and treadmill training at the 6th week. The patients were evaluated with Fugl-Meyer Assessment of Physical Performance(FMA), Barthel Idex(BI) and the Berg Balance Scale(BBS). ResultsThe functional outcome of the initial evaluation with FMA, BI and BBS were no-significantly different, 8 weeks later, that of group B were better than that of group A and group C (P<0.05～0.01), and that of group C were better than that of group A (P<0.05).ConclusionEarly treatment of partial body-weight support and treadmill training can help to improve the lower extremities function.

ObjectiveTo study the effect of THERA-vital Movement Therapy System on hemiplegic patients after stroke. Methods58 patients were divided into experimental group (n=30) or control group (n=28), the control group accepted routine stroke rehabilitation program, while the experimental group received muscle strength training with THERA-vital Movement Therapy System in addition. They were assessed with Fugl-Meyer Assessment (FMA) and Modified Barthel Index (MBI) before and after treatment. ResultsThere was no different between these two groups in both FMA and MBI before treatment （P＞0.05）. The scores of FMA and MBI significantly improved in both groups （P＜0.01）, and experimental group improved more than those in the control group （P＜0.01） after treatment. ConclusionMuscle strength training with THERA-vital Movement Therapy System is beneficial in improving motor function and activity of daily living in hemiplegic patient after stroke.

OBJECTIVETo explore the association between the abnormal phosphorylation sites found in Alzheimer disease (AD) tau and the inhibition of its biological activity.

METHODSUltracentrifugation, chromatography, manual Edman degradation and autosequence techniques were used to prepare and phosphorylate human recombinant tau, isolate and purify 32P tau peptides and determine phosphorylation sites.

RESULTSPhosphorylation of tau by casein kinase 1 (CK-1), cyclic AMP-dependent protein kinase (PKA) and glycogen synthetase kinase 3 (GSK-3) separately inhibited its biological activity and the inhibition of this activity by (CSK-3 was significantly increased if tau was prephosphorylated by CK-1 or PKA. The most potent inhibition was seen by a combined phosphorylation of tau with PKA and GSK-3. The treatment of tau by PKA and GSK-3 combination induced phosphorylation of tau at Ser-195, Ser-198, Ser-199, Ser-202, Thr-205, Thr-231, Ser-235, Ser-262, Ser-356, Ser-404, whereas Thr-181, Ser-184, Ser-262, Ser-356 and Ser-400 were phosphorylated by GSK-3 alone under the same condition.

CONCLUSIONPhosphorylation of tau by PKA plus GSK-3 at Thr-205 might play a key role in tau pathology in AD.

Alzheimer Disease ; metabolism ; Binding Sites ; Casein Kinases ; Cyclic AMP-Dependent Protein Kinases ; metabolism ; Glycogen Synthase Kinase 3 ; metabolism ; Humans ; In Vitro Techniques ; Microtubules ; metabolism ; Phosphorylation ; Protein Kinases ; metabolism ; tau Proteins ; metabolism

Objective:To explore the efficacy and safety of cryopreservation-free integrated autologous hematopoietic stem cell transplantation (HSCT) model for patients with multiple myeloma.Methods:A total of 96 patients with newly diagnosed multiple myeloma (NDMM) between July 31, 2020, and December 31, 2022, were retrospectively analyzed, of which 41 patients in the observation group received integrated non-cryopreserved transplantation mode. After hematopoietic stem cells were mobilized and collected, melphalan was started immediately for pre-transplant conditioning, and non-cryopreserved grafts from the medical blood transfusion refrigerator were directly injected intravenously into the patient within 24-48 h after the melphalan conditioning. The control group consisted of 55 patients who received traditional transplantation mode. After hematopoietic stem cells were collected, stem cell cryopreservation was performed in liquid nitrogen, and then the transplant plans were started at the right time. All patients received mobilization of autologous hematopoietic stem cells using the G-CSF combined with the plerixafor.Results:① A total of 34 patients (82.9% ) with VGPR plus CR in the observation group were significantly higher than 33 patients (60.0% ) in the control group ( P=0.016). ②Compared with the control group, the incidence of grade 1 oral mucosal inflammation was higher in the observation group ( P<0.001) ; however, the incidence of grades 2 and 3 oral mucosal inflammation was lower ( P=0.004, P=0.048), and neither group experienced grade 4 or above oral mucosal inflammation. The incidence of grade 1 diarrhea was higher in the observation group ( P=0.002), whereas the incidence of grade 3 diarrhea was lower ( P=0.007). No statistically significant difference was observed in the incidence of grade 4 diarrhea ( P=0.506), and neither group experienced grade 5 diarrhea. ③ The incidence of bacterial infection in the observation group was lower than that in the control group (34.1% vs 65.5%, P=0.002), whereas no statistically significant difference was observed in the incidence of fungal infection (29.3% vs 31.4%, P=0.863) and viral infection (4.88% vs 3.64%, P=0.831). ④No statistically significant difference was observed in the implantation time of granulocytes and platelets between the observation and control groups [10 (8-20) days vs 11 (8-17) days, P=0.501; 13 (10-21) days vs 15 (10-20) days, P=0.245]. ⑤ All patients did not receive lenalidomide treatment 100 days post-transplantation. At 30 days post-transplantation, the CTL, NK, and Th cell counts in the observation group were lower than those in the control group ( P<0.001, P=0.002, P=0.049), and the NKT cell counts were higher than those in the control group ( P=0.024). At 100 days post-transplantation, the CTL, NKT, and Th cell counts in the observation group were higher than those in the control group ( P=0.025, P=0.011, P=0.007), and no statistically significant difference in NK cell counts was observed between the two groups ( P=0.396). ⑥ The median follow-up was 18 (4-33) months. The overall 2-year survival rates of the observation and control groups post-transplantation were 91.5% and 78.2%, respectively ( P=0.337). The recurrence-free survival rates were 85.3% and 77.6%, respectively ( P=0.386), and the cumulative recurrence rates were 9.8% and 16.9%, respectively ( P=0.373) . Conclusion:In NDMM, the cryopreservation-free integrated autologous HSCT model can achieve similar therapeutic effects as traditional transplantation models, with lower rates of severe mucosal inflammation and infection compared with traditional transplantation models.

The condition of patients with severe traumatic brain injury (sTBI) complicated by corona virus 2019 disease (COVID-19) is complex. sTBI can significantly increase the probability of COVID-19 developing into severe or critical stage, while COVID-19 can also increase the surgical risk of sTBI and the severity of postoperative lung lesions. There are many contradictions in the treatment process, which brings difficulties to the clinical treatment of such patients. Up to now, there are few clinical studies and therapeutic norms relevant to sTBI complicated by COVID-19. In order to standardize the clinical treatment of such patients, Critical Care Medicine Branch of China International Exchange and Promotive Association for Medical and Healthcare and Editorial Board of Chinese Journal of Trauma organized relevant experts to formulate the Chinese expert consensus on clinical treatment of adult patients with severe traumatic brain injury complicated by corona virus infection 2019 ( version 2023) based on the joint prevention and control mechanism scheme of the State Council and domestic and foreign literatures on sTBI and COVID-19 in the past 3 years of the international epidemic. Fifteen recommendations focused on emergency treatment, emergency surgery and comprehensive management were put forward to provide a guidance for the diagnosis and treatment of sTBI complicated by COVID-19.